Unite Life Sciences has brought together the below experts to address some of the industry's most pressing questions when it comes to designing clinical trials. We have adaptive design, but what else can be considered in diverse approaches to treat cancer? What have we learned about what else might be considered to augment with real world evidence and other data sets that could be valuable to understand the safety and effectiveness of a new molecule? How can industry be “better” at designing trials to utilize resources in the best way possible?

Speakers:

• Michel Azoulay MD - Clinical Development Strategy, Sanofi
• Caroline Germa - Vice President, Head Clinical Development, Early Portfolio, Oncology R&D, AstraZeneca
• David S. Hong MD - Associate Vice President of Clinical Research, M.D. Anderson Cancer Center
• Kenneth G. Faulkner PhD - Vice President of eCOA Scientific Services, ERT

Fill out the form to start watching one of our dynamic sessions from October's virtual forum, Rethinking Clinical Trials in Oncology.